News and Trends 12 Sep 2022 First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease The first patient has been enrolled in a phase 3 study of a treatment for type 1A Charcot-Marie-Tooth Disease (CMT1A) in the U.S., it was announced today (September 12). Charcot-Marie-Tooth disease is a group of inherited conditions that damage the peripheral nerves and a treatment is being developed by French biopharmaceutical company, Pharnext. The PREMIER […] September 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […] September 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September 8) they have a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field. In 2018, science and technology company Merck, of which Sigma-Aldrich is a subsidiary, announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based […] September 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Lesaffre acquires genome editing company Recombia Biosciences Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Adocia takes steps with implants for treatment of type 1 diabetes French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant by achieving glycemic control without insulin injections in immunocompetent diabetic rats during a 132-day study. AdoShell Islets is an immuno-protective synthetic biomaterial containing islets of Langerhans. After implantation in diabetic animals, the islets encapsulated in AdoShell secrete insulin in […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Abivax pulls in €49.2M but needs more to complete ulcerative colitis program French biotech company Abivax has completed an oversubscribed €49.2 million ($49 million) financing round. This included U.S. and European biotech specialist investors, led by TCGX, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus, and Truffle Capital through the completion of two transactions. The first was a reserved capital increase of […] September 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Cancer drug for children and young people with glioblastoma given to patients in study Clinical-stage bio company, Onxeo, has announced that the first patients have been enrolled and treated in a phase 1b/2 clinical study. The study is to evaluate the efficacy and tolerability of AsiDNA2, a DDR inhibitor combined with radiotherapy in children, adolescents or young adults with relapsed high grade glioma (HGG). Onxeo, which focuses on drugs […] September 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Aug 2022Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva On this week’s podcast, we have conversations with ARCH Venture Partners’ managing director Kristina Burow; founder and CEO of Micropep Thomas Laurent; Kylie O’Keefe, SVP, commercial & corporate strategy at PTC Therapeutics, and Juan Carlos Jaramillo, chief medical officer of Valneva. ARCH Venture Partners closes $2.97B biotech fund ARCH Venture Partners has announced the closing […] August 12, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Bone Therapeutics and Medsenic set to combine in share for share deal Subject to the outcome of a shareholders’ meeting, Bone Therapeutics and Medsenic are set to combine their operations reducing risks and broadening portfolios. The companies announced they have signed a share for share binding contribution today (August 10) which will create new enterprise BioSenic. Brussels and Paris-based Bone Therapeutics is a cell therapy company that […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Opinion 8 Aug 2022 Building a healthtech industry in Europe to serve patients By Maryvonne Hiance, president of HealthTech For Care; and Christian Pierret, Former Minister Delegate for Industry The HealthTech For Care endowment fund, launched by France Biotech is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. Europe is just emerging from a health crisis that […] August 8, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Aug 2022 Abivax has approval granted to enroll ulcerative colitis patients in two studies Patients with moderate to severe ulcerative colitis (UC) can now be enrolled onto two phase 3 induction studies for a biotech company’s lead candidate drug. France-based Abivax SA is a phase 3 clinical stage biotech company that focuses on developing therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer. […] August 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence Sanofi and Innovent Biologics are to collaborate on providing medicines to patients in China with difficult-to-treat cancers. Innovent is a biopharmaceutical company with clinical development capabilities and a broad commercial footprint in China. Both companies said they are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III […] August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email